The U.S. Health Resources and Services Administration’s (HRSA) proposed replacement for its year-old 340B administrative dispute resolution (ADR) process has been under White House review for almost 100 days—nearly a month longer that the anticipated release date announced in November.
…
Critical access hospitals, rural referral centers, sole community hospitals, and free-standing cancer hospitals will not be getting access to voluntary 340B pricing on Bristol Myers Squibb’s (BMS) expensive myeloma drugs—a development certain to be a disappointment for rural providers.
340B covered entity allies in the U.S. House are booking an hour of floor speeches by members lauding the drug discount program next week Tuesday after all legislative business is finished.
SPONSORED CONTENT
Drastic federal cuts to the 340B program. Alarming changes to Gilead’s Advancing Access Program. If your organization is a federal grantee or health system providing HIV care and/or prevention services, you know there has never been a more important time to future-proof your program—while still offering the highest standards of compassionate care.
What’s more, how entities provide care to their communities is
…
Eleven of the 15 top-selling brand drugs in the United States are now subject to manufacturer-imposed 340B pricing restrictions, including eight in the past 90 days, a new analysis shows.
The brand name drug industry and the state of Arkansas have agreed on a litigation plan that could lead to a quicker federal court decision than now anticipated on the state’s one-of-a-kind law protecting 340B contract pharmacy arrangements.
…
The American Hospital Association (AHA) yesterday asked U.S. House and Senate party leaders to ensure that a must-pass spending bill next month protects hospitals from losing their 340B eligibility due to changes in patient and payer mix caused by the
…
Three drug manufacturers—including two that have imposed conditions on 340B contract pharmacy—posted public notices this week to 340B covered entities about refunds for charges above 340B ceiling prices.
U.S. Senate Finance Committee Chair Ron Wyden (D-Ore.) said this week that new Congressional Budget Office (CBO) findings on brand drug price increases “drives home the urgent need to pass robust drug pricing reforms.”
SPONSORED CONTENT
Are you attending the upcoming 340B Coalition Winter Conference in San Diego? Join us for breakfast!
Marriott Marquis San Diego Marina
Monday, January 31 | 8:30 a.m. PT
Omnicell 340B will be hosting a panel discussion with some of the most respected long-term experts on the 340B program at the upcoming 340B Coalition
…*Sign up for news summaries and alerts from 340B Report
